tailieunhanh - Ruxolitinib in GvHD (RIG) study: A multicenter, randomized phase 2 trial to determine the response rate of Ruxolitinib and best available treatment (BAT) versus BAT in steroid-refractory acute graft-versushost disease (aGvHD) (NCT02396628)

Graft-versus-Host Disease (GvHD) causes significant morbidity and mortality in patients after allogeneic stem cell transplantation. Donor T-cells cause inflammation and tissue damage in GvHD target organs such as liver, gut and skin. | Ruxolitinib in GvHD RIG study A multicenter randomized phase 2 trial to determine the response rate of Ruxolitinib and best available treatment BAT versus BAT in steroid-refractory acute graft-versushost disease aGvHD NCT02396628

TÀI LIỆU LIÊN QUAN
TỪ KHÓA LIÊN QUAN